Nature Search

Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia

Michela Ansuinelli
Nadia Peragine
Robin Foà
Research22 Jan 2026
Leukemia

P: 1-10
Proteasome-dependent truncation of the negative heterochromatin regulator Epe1 mediates antifungal resistance

Here, the authors find that histone demethylase Epe1-mediated stress resistance is regulated by proteasome-dependent truncation, allowing heterochromatin to reprogram gene expression that confers antifungal resistance to some fission yeast cells in the population.

Imtiyaz Yaseen
Sharon A. White
Robin C. Allshire
Research25 Jul 2022
Nature Structural & Molecular Biology

Volume: 29, P: 745-758
TREX is a conserved complex coupling transcription with messenger RNA export

Katja Sträßer
Seiji Masuda
Ed Hurt
Research28 Apr 2002
Nature

Volume: 417, P: 304-308
Assessment of sustainable baits for passive fishing gears through automatic fish behavior recognition

Alexa Sugpatan Abangan
Kilian Bürgi
Robin Faillettaz
ResearchOpen Access07 Jun 2024
Scientific Reports

Volume: 14, P: 1-11
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Giovanni Caocci
Olga Mulas
Giorgio La Nasa
ResearchOpen Access08 Jun 2020
Blood Cancer Journal

Volume: 10, P: 1-6
Defects in DNA ligase I trigger PCNA ubiquitylation at Lys 107

DNA ligase I links newly synthesized DNA fragments. DNA ligase I deficiency causes ubiquitylation of PCNA in yeast and human by the E2 variant Mms26, Ubc47 and the E3 Rad5, which is required for activation of the DNA damage response and cell viability.

Sapna Das-Bradoo
Hai Dang Nguyen
Anja-Katrin Bielinsky
Research13 Dec 2009
Nature Cell Biology

Volume: 12, P: 74-79
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system

Joshua Pankrac
Katja Klein
Jamie F. S. Mann
ResearchOpen Access19 Jan 2018
npj Vaccines

Volume: 3, P: 1-10
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis

Catherine Labbaye
Isabella Spinello
Cesare Peschle
Research22 Jun 2008
Nature Cell Biology

Volume: 10, P: 788-801
Integration of [¹⁸F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

Riccardo Dondolin
Federico Garrou
Riccardo Moia
ResearchOpen Access08 Jul 2025
Leukemia

Volume: 39, P: 2207-2214
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study

Gianluca Cavallaro
Davide Lazzarotto
Federico Lussana
ResearchOpen Access02 Jun 2025
Bone Marrow Transplantation

Volume: 60, P: 1228-1235
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Nicolas Boissel
Sabina Chiaretti
Alessandro Rambaldi
ResearchOpen Access04 Jan 2023
Blood Cancer Journal

Volume: 13, P: 1-9
Expression of bak in S. pombe results in a lethality mediated through interaction with the calnexin homologue Cnx1

Catherine N Torgler
Mariastella de Tiani
Eric Meldrum
Research01 May 1997
Cell Death & Differentiation

Volume: 4, P: 263-271
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò
Thomas Chatzikonstantinou
Paolo Ghia
Research09 Jul 2020
Leukemia

Volume: 34, P: 2354-2363
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Riccardo Bomben
Francesca Maria Rossi
Valter Gattei
ResearchOpen Access18 Feb 2023
Leukemia

Volume: 37, P: 914-918
In Ph+BCR-ABL1^P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Michele Baccarani
Ilaria Iacobucci
Francesco Passamonti
Research08 Oct 2019
Leukemia

Volume: 34, P: 929-931
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Massimo Gentile
Fortunato Morabito
Valter Gattei
Research14 Apr 2020
Leukemia

Volume: 35, P: 235-238
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement

Roberta La Starza
Monica Messina
Cristina Mecucci
Research02 Feb 2018
Leukemia

Volume: 32, P: 1807-1810
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

Massimo Gentile
Tait D. Shanafelt
Fortunato Morabito
Research20 Mar 2018
Leukemia

Volume: 32, P: 1869-1873
PSGL-1 decorated with sialyl Lewis^a/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement

Michael O’Dwyer
Lucy Kirkham-McCarthy
Alessandro Natoni
ResearchOpen Access19 Jan 2024
Scientific Reports

Volume: 14, P: 1-12
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT

Jordi Esteve
Sebastian Giebel
Arnon Nagler
Research04 Feb 2021
Leukemia

Volume: 35, P: 2232-2242
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou
Anargyros Kapetanakis
Paolo Ghia
ResearchOpen Access01 Nov 2021
Leukemia

Volume: 35, P: 3444-3454
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?

Ilaria Del Giudice
Robin Foà
Reviews14 Oct 2023
Leukemia

Volume: 37, P: 2339-2342
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Francesc Bosch
Guy Cantin
Véronique Leblond
ResearchOpen Access27 Aug 2019
Leukemia

Volume: 34, P: 441-450
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

Andrea Visentin
Laura Bonaldi
Livio Trentin
ResearchOpen Access18 Jun 2019
British Journal of Cancer

Volume: 121, P: 150-156
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Stephan Stilgenbauer
Veronique Leblond
Francesc Bosch
ResearchOpen Access27 Apr 2018
Leukemia

Volume: 32, P: 1778-1786
Daniel Catovsky (1937–2022)

Victor Hoffbrand
Robin Foà
Comments & Opinion03 Mar 2023
Leukemia

Volume: 37, P: 954-955
Prof. Daniel Catovsky Buenos Aires 19 September 1937—London 2 December 2022

Robin Foà
Junia V. Melo
Kanti K. Rai
Comments & Opinion28 Jan 2023
Bone Marrow Transplantation

Volume: 58, P: 616-617
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Massimo Gentile
Enrica Antonia Martino
Fortunato Morabito
CorrespondenceOpen Access16 Sept 2020
Blood Cancer Journal

Volume: 10, P: 1-3
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol

Ursula La Rocca
Maria Paola Perrone
Anna Paola Iori
Correspondence04 Mar 2019
Bone Marrow Transplantation

Volume: 54, P: 1717-1720
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Massimo Breccia
Elisabetta Abruzzese
Levato Luciano
Correspondence18 Jun 2020
Leukemia

Volume: 34, P: 2260-2261
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Sebastian Giebel
David I. Marks
Hervé Dombret
Reviews01 Nov 2018
Bone Marrow Transplantation

Volume: 54, P: 798-809

Search

Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia

Proteasome-dependent truncation of the negative heterochromatin regulator Epe1 mediates antifungal resistance

TREX is a conserved complex coupling transcription with messenger RNA export

Assessment of sustainable baits for passive fishing gears through automatic fish behavior recognition

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Defects in DNA ligase I trigger PCNA ubiquitylation at Lys 107

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system

A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis

Integration of [¹⁸F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Expression of bak in S. pombe results in a lethality mediated through interaction with the calnexin homologue Cnx1

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

In Ph+BCR-ABL1^P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

PSGL-1 decorated with sialyl Lewis^a/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Daniel Catovsky (1937–2022)

Prof. Daniel Catovsky Buenos Aires 19 September 1937—London 2 December 2022

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

Search

Quick links

Search

Filter By:

Search

Quick links